视网膜母细胞瘤蛋白
基因敲除
视网膜母细胞瘤
胰岛素样生长因子1受体
细胞凋亡
癌症研究
下调和上调
细胞生长
生长抑制
细胞周期
生物
生长因子
遗传学
受体
基因
作者
Su-Chan Lee,Satoshi Nakata,Lujain Alaali,Kaixuan Wang,Pei‐Jane Tsai,Khoa Pham,Brent A. Orr,Quynh T. Tran,Laura Asnaghi,Eric H. Raabe,Charles G. Eberhart
出处
期刊:Neuro-oncology
[Oxford University Press]
日期:2025-04-10
卷期号:27 (7): 1715-1728
标识
DOI:10.1093/neuonc/noaf096
摘要
Abstract Background BCL-6 corepressor (BCOR) loss-of-function alterations are common in clinically aggressive retinoblastoma. The study aim was to determine if BCOR loss promotes the growth and dissemination of retinoblastoma cells, and identify the pathways it regulates in these retinal tumors of childhood. Methods Gain- and loss-of-function strategies were used to modulate BCOR levels in a panel of retinoblastoma cell lines, and the effects on proliferation, clonogenicity, apoptosis, and migration were assessed in vitro and in murine xenograft models. Results BCOR knockdown or knockout in retinoblastoma lines with high protein levels increased tumor growth, invasion, clonogenicity, and chemoresistance in vitro, while increased expression in low BCOR lines slowed growth. Growth of retinoblastoma xenografts was similarly sensitive to BCOR gain or loss. BCOR reduction resulted in upregulation of IGF1 and activation of IGF1 receptor (IGF1R) signaling, and the effects of IGF1R inhibition were dependent on BCOR level. In vitro, reduction of retinoblastoma growth and induction of apoptosis by the IGF1R inhibitors linsitinib and AEW541 were also significantly stronger in cells with low BCOR as compared to controls. Both linsitinib and AEW541 suppressed colony formation in a dose-dependent manner in BCOR knockout or knockdown cells. Finally, high BCOR levels rendered retinoblastoma xenografts insensitive to linsitinib. Conclusions Loss of BCOR function is associated with more aggressive retinoblastoma cell line growth and chemoresistance, at least in part due to increased IGF1R signaling. Inhibiting IGF1R pharmacologically had a marked anti-tumor effect in aggressive retinoblastoma lacking BCOR, suggesting it as a new therapeutic target, although this still needs to be confirmed in clinical samples with BCOR mutations.
科研通智能强力驱动
Strongly Powered by AbleSci AI